Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosylation factor-like GTPase 17B (ARL17B) is a member of the ARF (ADP-ribosylation factor) family of small GTPases, specifically the ARF-like (ARL) group within the Ras superfamily. It is predicted to possess GTP binding and intrinsic GTPase activity, suggesting a regulatory function in intracellular protein and vesicle transport, potentially modulating vesicle budding and uncoating at the Golgi apparatus. ARL17B localizes to the Golgi apparatus and is implicated in membrane trafficking, with genetic, epigenetic, and evolutionary studies pointing to a role in disorders of the central nervous system, such as progressive supranuclear palsy, Parkinson’s disease, and developmental dyslexia—often due to its altered expression or involvement in chromosomal rearrangements in the 17q21.31 region. The exact molecular and cellular function of ARL17B remains to be fully elucidated, and to date, no drugs are known to target this protein, nor is it regarded as a validated pharmacological target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADP-ribosylation factor-like GTPase 17B (ARL17B).